Core Viewpoint - China Galaxy Securities Co., Ltd. has successfully issued a total of 1 billion RMB in technology innovation corporate bonds aimed at professional investors, with a final coupon rate of 1.79% and a subscription multiple of 5.37 times [2]. Group 1 - The company has received approval from the China Securities Regulatory Commission for the public issuance of technology innovation corporate bonds, with a total face value not exceeding 5 billion RMB [1]. - The bonds have a term of 3 years and were issued at a price of 100 RMB per bond, utilizing a book-building method targeted at professional investors [1]. - The actual issuance of the bonds concluded on March 23, 2026, with a total issuance scale of 1 billion RMB [2]. Group 2 - The company's directors, senior management, and shareholders with over 5% ownership did not participate in the bond subscription [3]. - The main underwriter, China International Capital Corporation, and its affiliates participated in the bond subscription, with amounts of 80 million RMB and 300 million RMB respectively [3]. - The subscription quotes and procedures adhered to relevant laws and regulations [3].

Core Viewpoint - China Coal Energy Co., Ltd. has received approval to issue debt financing tools totaling up to RMB 40 billion, including medium-term notes, with a validity period until December 31, 2027 [1] Group 1 - The company’s board approved the issuance of debt financing tools at the annual shareholders' meeting on June 27, 2025, with a total amount not exceeding RMB 40 billion [1] - The company has received a registration notice from the China Interbank Market Dealers Association, allowing it to register medium-term notes amounting to RMB 5 billion, valid for two years from the date of the notice [1] - The underwriting for the medium-term notes will be jointly led by CITIC Securities Co., Ltd., Industrial and Commercial Bank of China, and CITIC Bank [1] Group 2 - The company will issue medium-term notes in accordance with the registration notice and relevant regulations, ensuring proper information disclosure [2]

Group 1 - The core announcement is about the change of the Hong Kong business address of the company to 32nd Floor, One Exchange Square, 8 Connaught Place, Central, Hong Kong [1] - The company assures that all other information remains unchanged [1] - The announcement is made by the board of directors of the company, confirming the accuracy and completeness of the information provided [1][3]

Group 1 - The core point of the article is that Ibuprofen granules have been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024 Edition) as a Class B product, indicating strong demand and clinical application for this common analgesic and antipyretic drug [1] - Ibuprofen is effective in alleviating mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea, and is also suitable for fever caused by common colds or influenza [1] - Xinhua Pharmaceutical, as a leading enterprise in the integrated production of ibuprofen raw materials and formulations in China, has established a complete ibuprofen industry chain from pharmaceutical intermediates to raw materials and formulations [1] Group 2 - The company has developed a diverse range of ibuprofen products, including ibuprofen tablets, ibuprofen pseudoephedrine tablets, ibuprofen suspension, ibuprofen sustained-release capsules, ibuprofen suspension drops, and the newly approved ibuprofen granules, catering to various clinical medication needs [1] - The company relies on a self-controlled raw material supply system, a strict and standardized quality management system, and continuous R&D innovation capabilities to enhance its ibuprofen product matrix [1] - Recently, Xinhua Pharmaceutical's subsidiary, Xinda Pharmaceutical, received approval from the National Medical Products Administration for the market launch of ibuprofen granules [2]

Core Viewpoint - China Coal Energy Co., Ltd. has received approval for the registration of medium-term notes amounting to RMB 50 billion, as part of a broader authorization to issue debt financing tools totaling up to RMB 400 billion until December 31, 2027 [1][2]. Group 1 - The company's board approved the issuance of debt financing tools at the 2024 annual shareholders' meeting on June 27, 2025, with a total limit of RMB 400 billion [1][2]. - The registered amount for the medium-term notes is RMB 50 billion, valid for two years from the date of the acceptance notice issued by the China Interbank Market Dealers Association [1][2]. - The underwriting for the medium-term notes will be jointly led by CITIC Securities Co., Ltd., Industrial and Commercial Bank of China, and CITIC Bank [1][2]. Group 2 - The company plans to issue the medium-term notes in tranches during the registration validity period and will disclose the issuance results through channels recognized by the Dealers Association [3][4]. - The issuance will comply with the relevant rules and guidelines for non-financial corporate debt financing tools [4].

Core Viewpoint - Southbound funds have significantly increased their holdings in China Software International (00354.HK), indicating strong investor interest in the company [1] Group 1: Southbound Fund Activity - On March 23, southbound funds increased their holdings by 5.512 million shares of China Software International [1] - Over the past 5 trading days, there have been 4 days of net increases, totaling 8.722 million shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 48.742 million shares [1] - Currently, southbound funds hold 949 million shares of China Software International, representing 34.73% of the company's total issued ordinary shares [1] Group 2: Company Overview - China Software International is an investment holding company that provides global technology software and IT services [1] - The company operates through two main segments: Technology Professional Services and Internet Information Technology Services [1] - Its primary business focuses on the development of generative artificial intelligence (AIGC), large model software and hardware sales, and digital transformation consulting services for enterprise resource planning (ERP) [1] - Key products include the "Question Series" solutions, large model application integrated machines, and Lingxi AI application platforms [1] - The company serves various sectors, including water conservancy, transportation, government platforms, military, energy, education, and finance, operating in both domestic and international markets [1]

Core Viewpoint - Southbound funds have significantly increased their holdings in China Construction Bank, indicating strong investor interest and confidence in the bank's performance [1] Group 1: Southbound Fund Activity - On March 23, southbound funds increased their holdings by 1.343 million shares of China Construction Bank (00939.HK) [1] - Over the past five trading days, there have been five days of net increases, totaling 22.5 million shares [1] - In the last 20 trading days, there were 18 days of net increases, amounting to 34.1 million shares [1] - Currently, southbound funds hold 35.1 billion shares of China Construction Bank, representing 14.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - China Construction Bank Corporation is a commercial bank with primary business segments including corporate banking and personal banking [1] - Corporate banking services encompass enterprise deposits, corporate loans, asset custody, enterprise annuities, trade financing, international settlement, international financing, and value-added services [1] - Personal banking services include personal savings, loans, credit card services, private banking services, foreign exchange trading, and gold trading [1] - The bank operates in both domestic and overseas markets [1]

Group 1 - The announcement date is March 24, 2026 [1] - The changes have been approved by the 73rd meeting of the second board of Shanghai Guotai Haitong Securities Asset Management Co., Ltd [1] - The changes have been filed in accordance with the new Securities Law requirements [1] Group 2 - Information regarding new senior management personnel is included [1] - Information regarding departing senior management personnel is also provided [1] - Other matters that need to be explained are mentioned [1]

Group 1 - The core point of the article is that Shangrong Medical (002551) has reported a decline in stock price and has announced a guarantee for a credit facility for its wholly-owned subsidiary [1] - As of March 23, 2026, the stock closed at 3.27 yuan, down 7.37% from the previous trading day, with a total market value of 2.765 billion yuan [1] - The company held a board meeting on March 23, 2026, to approve a guarantee for its subsidiary Shenzhen Shangrong Medical Engineering Co., Ltd. to apply for a credit facility of 72 million yuan from Industrial and Commercial Bank of China [1] Group 2 - The guarantee is for a credit facility that includes bank acceptance bills, letters of credit, non-financing guarantees, and trade financing [1] - This guarantee is a continuation of the original credit limit and does not require approval from the shareholders' meeting [1] - The guaranteed party is a wholly-owned subsidiary of the company and is not a dishonest executor [1]

Core Viewpoint - Ganfeng Lithium (01772) announced the resignation of Ms. Xu Yixin as an independent non-executive director and proposed the appointment of Mr. Xu Jianzhang as an independent non-executive director, effective from March 23, 2026 [1] Group 1 - Ms. Xu Yixin's resignation is due to the expiration of her term, and Mr. Xu Jianzhang has been elected as an independent non-executive director at the extraordinary general meeting scheduled for March 11, 2026 [1] - Following Ms. Xu Yixin's resignation, Mr. Xu Jianzhang will also serve as the chairman of the board's remuneration and assessment committee starting from March 23, 2026 [1] - Mr. Xu Guanghua, who has served as an independent non-executive director since March 24, 2020, will also resign on March 23, 2026, after completing his six-year term [1] Group 2 - Mr. Xu Guanghua will continue to fulfill his responsibilities as an independent non-executive director, nomination committee chairman, and audit committee member until the new independent non-executive director is elected at the next shareholders' meeting [1]